305 completed, 81 terminated, 58 unknown, 30 recruiting. 308 Phase 2, 124 Phase 1, 83 Phase 3, 20 Phase 4, 7 Not applicable.
Follow this drug Literature Review of Imatinib Mesylate trials Research Report on Imatinib Mesylate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis Tofacitinib, Imatinib, tofacitinib Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 135 | 2026-08-01 | 2026-08-03 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) Velzatinib, Imatinib - Gastrointestinal Stromal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 800 | 2026-07-27 | 2026-10-05 |
| KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) KQB198, Imatinib (Gleevec) - GIST - Gastrointestinal Stromal Tumor, GIST | Phase 2 | Recruiting | Kumquat Biosciences Inc. | 46 | 2026-06-23 | 2026-08-10 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Imatinib, Fampridine - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | University of California, San Diego | 18 | 2026-05-13 | 2026-05-27 |
| Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients Tyrosine kinase Inhibitors (Imatinib & Nilotinib) - Chronic Myeloid Leukemia | Not yet recruiting | Assiut University | 75 | 2026-05-01 | 2026-02-18 | |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Victoria Biomedical Research Institute | 1116 | 2026-01-20 | 2026-06-29 |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy TKIs - Chronic Myelogenous Leukemia - Chronic Phase | Recruiting | Novartis Pharmaceuticals | 1000 | 2025-12-17 | 2026-07-20 | |
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) Imatimib Mesylate, Placebo - Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis | Phase 1 | Recruiting | Columbia University | 20 | 2025-10-20 | 2026-01-21 |
| Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Imatinib, Artesunate - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Obafemi Awolowo University | 75 | 2025-07-01 | 2026-10-14 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-21 |
| Imatinib and Trametinib for KRAS-mutated Solid Tumor Imatinib, Trametinib - Solid Tumor Cancer | Phase 1 | Recruiting | China Medical University Hospital | 10 | 2025-05-10 | 2025-05-08 |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) ziftomenib, imatinib mesylate - Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer | Phase 1 | Recruiting | Kura Oncology, Inc. | 157 | 2025-03-27 | 2026-02-05 |
| Precision Cancer Therapy in Rare Cancers Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm | Phase 2 | Recruiting | Oslo University Hospital | 96 | 2025-03-20 | 2025-03-26 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis Imatinib, Compound sodium lactate solution - Sepsis, Fluid Overload | Phase 1 / Phase 2 | Unknown | Belfast Health and Social Care Trust | 65 | 2024-12-01 | 2024-10-04 |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease Rovadicitinib, Imatinib, Methotrexate - Graft-versus-host Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 182 | 2024-11-20 | 2025-12-08 |
Showing 20 of 517. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (144) · Gastrointestinal Stromal Tumors (71) · Leukemia (69) · Leukemia, Myeloid, Chronic-Phase (50) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (43) · Blast Crisis (22) · Brain Neoplasms (15) · Neoplasms (15) · Philadelphia Chromosome (14) · Melanoma (13) · Glioblastoma (12) · Leukemia, Myeloid, Accelerated Phase (12) · Leukemia, Myeloid, Acute (12) · Neoplasm Metastasis (12) · Sarcoma (12)
Novartis Pharmaceuticals (60) · National Cancer Institute (NCI) (42) · M.D. Anderson Cancer Center (32) · Novartis (9) · Asan Medical Center (8) · Bristol-Myers Squibb (8) · Gruppo Italiano Malattie EMatologiche dell'Adulto (7) · OHSU Knight Cancer Institute (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Poitiers University Hospital (6) · University of Bologna (6) · Dana-Farber Cancer Institute (5) · Duke University (5) · Indiana University (5) · Memorial Sloan Kettering Cancer Center (5)
United States (263) · France (66) · Italy (62) · Germany (57) · China (44) · United Kingdom (44) · Canada (43) · South Korea (43) · Spain (38) · Belgium (30) · Australia (29) · Netherlands (28) · Austria (24) · Sweden (21) · Japan (20)
Michele Baccarani, MD (7) · Jorge E Cortes, MD (6) · Ilana Monteleone (4) · Anne S. Tsao, MD (3) · David A. Reardon, MD (3) · Jorge E. Cortes, MD (3) · Anjali Advani, MD (2) · Annick Desjardins, MD, FRCPC (2) · Brian J. Druker, MD (2) · Christopher Logothetis, MD (2)
PMID 23620574, PMID 25361995, PMID 28835440, PMID 30885996, PMID 19451433, PMID 19797518, PMID 21387287, PMID 21447834, PMID 21450900, PMID 22692507, PMID 23403476, PMID 23515925, PMID 24859364, PMID 28273028, PMID 28572163, PMID 32499241, PMID 33242441, PMID 34473343, PMID 35235189, PMID 37553873, PMID 10636102, PMID 11057895, PMID 11215292, PMID 11705489, PMID 12094370, PMID 12528778, PMID 12531805, PMID 12538485, PMID 12637609, PMID 12957454, PMID 15010069, PMID 15070706, PMID 15231574, PMID 15315963, PMID 15592836, PMID 15659505, PMID 16098458, PMID 16105981, PMID 16110036, PMID 16293410, PMID 16344315, PMID 16550259, PMID 16556888, PMID 16565971, PMID 16624552, PMID 16710031, PMID 16876399, PMID 16914578, PMID 17032921, PMID 17046465
2005 (7), U10CA032102 (7), 2008 (5), P30CA015704 (5), 2017 (4), 2023 (4), P30CA016672 (4), P30CA072720 (4), U10CA031946 (4), U10CA098543 (4), U10CA180888 (4), 2009 (3), N01CM62202 (3), U01CA062487 (3), U01CA062502 (3)